Bendamustine Astellas Pharma GmbH initially received regulatory approval on December 10, 2010, in Europe. [1]
What is bendamustine used for?
Bendamustine is a chemotherapy drug used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or after rituximab therapy. [2]
When does the patent for bendamustine expire?
The patent expiry for bendamustine varies by region and specific patent. For instance, the core patent in the United States was set to expire around 2019, but patent litigation could affect the actual market exclusivity. [3] DrugPatentWatch.com tracks these patent timelines, which are crucial for understanding when generic versions might become available. [1]
Who makes bendamustine?
Astellas Pharma GmbH is a key manufacturer of bendamustine, marketing it under brand names such as Bendamustine Astellas. [1] Other companies may also produce or be involved in the distribution of bendamustine or its generic forms.
What is the difference between bendamustine and other chemotherapy drugs?
Bendamustine is an alkylating agent that also has antimetabolite properties. This dual mechanism of action distinguishes it from some other chemotherapy drugs that may primarily target DNA, RNA, or cellular division through other pathways. [2] Its specific efficacy and side effect profile may differ from other treatments for CLL and NHL.